Editas Medicine Inc. (NASDAQ:EDIT) currently has a “Sell” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Sell” signal. 10 – 8 Day Moving Average Hilo Channel shows “Hold” signal. While 20-Day Moving Average VS Current Price shows “Sell” Signal.
Editas Medicine Inc. (NASDAQ:EDIT) gained 3.65 Percent and closed its previous trading session at $28.66. The stock traded with the average Volume of 1.02 Million at the end of last session.
Editas Medicine Inc. (NASDAQ:EDIT) has the Market Capitalization of 1.39 Billion. The Stock has its 52-week High of $45.02 and 52-Week Low of $17.35 and it touched its 52-week high on 03/09/18 and 52-Week Low on 08/21/17
The company reported its last earnings Actual EPS of $-0.82/share. While, the analyst predicted that the company could provide an EPS of $-0.67/share. Hence the difference between Predicted EPS and Actual EPS reported is $-0.15/share which shows an Earnings Surprise of -22.4 Percent.
Sell side analysts plays vital role in buying and selling a stock where 0 analysts rated Editas Medicine Inc. (NASDAQ:EDIT) as Buy, 0 analysts given Outperform signal, 1 reported Hold, and 0 analysts rated the stock as Sell.
The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -11.59% where SMA50 and SMA200 are -19.45% and -12.81% respectively.
The company shows its Return on Assets (ROA) value of -32.4%. The Return on Equity (ROE) value stands at -58.7%. While it’s Return on Investment (ROI) value is -48.2%.
Editas Medicine Inc. (NASDAQ:EDIT) currently has a Weekly Volatility of 7.20% percent while its Monthly Volatility is at 6.02% percent. While talking about Performance of the Stock, Editas Medicine Inc. currently has a Weekly performance of -2.81%, monthly performance percentage is -24.58 percent, Quarterly performance is -14.6 percent, 6 months performance shows a percent value of -13.88% and Yearly Performance is 59.4 percent.
Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts.